Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

References

• Robak T, Kasznicki M. Alkylating agents and nucleoside analogs in the treatment of B-cell chronic lymphocityc leukemia. Leukemia 2002;16:1015–1027.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W, et al Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA, et al Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007–3015.
   PubMed Web of Science ®Google Scholar
• Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–1481.
   PubMed Web of Science ®Google Scholar
• Chadha P, Rademaker AW, Mendiratta P, et al Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241–246.
   PubMed Web of Science ®Google Scholar
• Robak T, Bloński JZ, Kasznicki M, et al Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia - updated results of the multicentre study of 378 patients. Br J Haematol 2000;108:357–368.
   PubMed Web of Science ®Google Scholar
• Robak T, Bloński JZ, Kasznicki M, et al Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723–2729.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J, et al Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy in chronic lymphocytic leukaemia: updated results of PALGCLL3 trial. Leuk Lymphoma 2007;48(Suppl.): 162.
   Google Scholar
• Karlsson KA, Strömberg M, Jönsson V, Mulligan SP, Liliemark J, Juliusson G. Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukaemia (CLL). First results from the International Randomized Phase III trial. Blood 2007;110(Suppl. 1):194a (Abstract 630).
   Google Scholar
• Hainsworth JD, Litchy S, Burris HA 3rd, et al Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;15:4261–4267.
   Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, et al Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity to either drug alone. Br J Haematol 2001;114:800–809.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, et al Addition of rituximab to fludarabine may prolong progression free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: in an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49–53.
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107:1542–1550.
   PubMed Web of Science ®Google Scholar
• Laszlo D, Rabascio C, Andreola G, et al Expression of the human concentrative nucleotide transporter (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's macroglobulinemia (WM), undergoing a combination treatment with cladribine (2-CdA) and rituximab. Blood 2007;110(Suppl. 1):408a (Abstract 1357).
   Google Scholar
• Cheson BD, Bennett JM, Grever M, et al National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986–994.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, et al ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Eng J Med 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M, et al International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia 2007;21:956–964.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink AM, et al Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and R (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1):125 (Abstract 325).
   Google Scholar
• Bosch F, Muntanola A, Villamor N, et al Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in prevously untreated chronic lymphocytic leukemia (CLL). Blood 2007;110(Suppl. 1):193a (Abstract 626).
   PubMed Web of Science ®Google Scholar
• Saven A, Carrera CJ, Carson DA, et al 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991;5(Suppl. 1):133–138.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. High complete remission rate from 2-chlordeoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 1993;11:679–689.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996;7:373–379.
   PubMed Web of Science ®Google Scholar
• Saven A, Lemon RH, Kosty M, et al 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13:570–574.
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Urbanska-Rys H, Gora-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004;45:937–944.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Christiansen I, Hansen MM, et al Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996;14:2160–2166.
   PubMed Web of Science ®Google Scholar
• Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992;10:1514–1518.
   PubMed Web of Science ®Google Scholar
• Betticher DC, Ratschiller D, Hsu Schmitz S-F, et al Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann Oncol 1998;9:721–726.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG et al Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, et al Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.
   PubMed Web of Science ®Google Scholar
• Lamanna N, Jurcic JG, Noy A, et al Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009;27:491–497.
   PubMed Web of Science ®Google Scholar
• Cramer P, Goede V, Jenke P, Busch R, Hallek M, Eichhorst B. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III trials of the German CLL Study Group. Blood 2006;108(Suppl. 1):804a (Abstract 2840).
   PubMed Web of Science ®Google Scholar
• Döhner H, Fischer K, Bentz M, et al p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580–1589.
   PubMed Web of Science ®Google Scholar